Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Interferon alpha: Phase III

AMAR said that its 24-week, 241-patient U.S. Phase III trial of oral interferon alpha to

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE